Selected research
Market Analysis & Forecast
Global Anti-Neprilysin Market Analysis and Forecast 2026-2032
Market perspective
The global Anti-Neprilysin market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.
The North America market for Anti-Neprilysin is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.
Europe market for Anti-Neprilysin is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.
Read the full market overview
Asia-Pacific market for Anti-Neprilysin is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.
The China market for Anti-Neprilysin is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.
The major global companies of Anti-Neprilysin include Novartis International AG, Theravance Biopharma Inc., Pharmaleads SA, Oceanic Pharmachem Pvt. Ltd, Cipla Limited and Bioprojet SCR, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.
Report Includes
This report presents an overview of global market for Anti-Neprilysin, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.
This report researches the key producers of Anti-Neprilysin, also provides the revenue of main regions and countries. Of the upcoming market potential for Anti-Neprilysin, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Anti-Neprilysin revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Anti-Neprilysin market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Anti-Neprilysin revenue, projected growth trends, production technology, application and end-user industry.
Anti-Neprilysin Segment by Company
Novartis International AG
Theravance Biopharma Inc.
Pharmaleads SA
Oceanic Pharmachem Pvt. Ltd
Cipla Limited
Bioprojet SCR
Anti-Neprilysin Segment by Type
LHW-090
PL-265
STR-324
TD-0714
Sacubitril
Anti-Neprilysin Segment by Application
Retail Pharmacies
Online Pharmacies
Hospital Pharmacies
Anti-Neprilysin Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Study Objectives
1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.
2. To present the key players, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Anti-Neprilysin market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Anti-Neprilysin and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Anti-Neprilysin.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Revenue of Anti-Neprilysin in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 4: Detailed analysis of Anti-Neprilysin company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Anti-Neprilysin revenue, gross margin, and recent development, etc.
Chapter 8: North America by type, by application and by country, revenue for each segment.
Chapter 9: Europe by type, by application and by country, revenue for each segment.
Chapter 10: China type, by application, revenue for each segment.
Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.
Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.
Chapter 13: The main concluding insights of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- LHW-090
- PL-265
- STR-324
- TD-0714
- Sacubitril
Applications
- Retail Pharmacies
- Online Pharmacies
- Hospital Pharmacies
Companies covered
- Novartis International AG
- Theravance Biopharma Inc.
- Pharmaleads SA
- Oceanic Pharmachem Pvt. Ltd
- Cipla Limited
- Bioprojet SCR
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Anti-Neprilysin Market by Type
- 1.2.1 Global Anti-Neprilysin Market Size by Type, 2021 VS 2025 VS 2032
- 1.2.2 LHW-090
- 1.2.3 PL-265
- 1.2.4 STR-324
- 1.2.5 TD-0714
- 1.2.6 Sacubitril
- 1.3 Anti-Neprilysin Market by Application
- 1.3.1 Global Anti-Neprilysin Market Size by Application, 2021 VS 2025 VS 2032
- 1.3.2 Retail Pharmacies
- 1.3.3 Online Pharmacies
- 1.3.4 Hospital Pharmacies
- 1.4 Assumptions and Limitations
- 1.5 Study Goals and Objectives
2 Anti-Neprilysin Market Dynamics
- 2.1 Anti-Neprilysin Industry Trends
- 2.2 Anti-Neprilysin Industry Drivers
- 2.3 Anti-Neprilysin Industry Opportunities and Challenges
- 2.4 Anti-Neprilysin Industry Restraints
3 Global Growth Perspective
- 3.1 Global Anti-Neprilysin Market Perspective (2021-2032)
- 3.2 Global Anti-Neprilysin Growth Trends by Region
- 3.2.1 Global Anti-Neprilysin Market Size by Region: 2021 VS 2025 VS 2032
- 3.2.2 Global Anti-Neprilysin Market Size by Region (2021-2026)
- 3.2.3 Global Anti-Neprilysin Market Size by Region (2027-2032)
4 Competitive Landscape by Players
- 4.1 Global Anti-Neprilysin Revenue by Players
- 4.1.1 Global Anti-Neprilysin Revenue by Players (2021-2026)
- 4.1.2 Global Anti-Neprilysin Revenue Market Share by Players (2021-2026)
- 4.1.3 Global Anti-Neprilysin Players Revenue Share Top 10 and Top 5 in 2025
- 4.2 Global Anti-Neprilysin Key Players Ranking, 2024 VS 2025 VS 2026
- 4.3 Global Anti-Neprilysin Key Players Headquarters & Area Served
- 4.4 Global Anti-Neprilysin Players, Product Type & Application
- 4.5 Global Anti-Neprilysin Players Establishment Date
- 4.6 Market Competitive Analysis
- 4.6.1 Global Anti-Neprilysin Market CR5 and HHI
- 4.6.3 2025 Anti-Neprilysin Tier 1, Tier 2, and Tier 3
5 Anti-Neprilysin Market Size by Type
- 5.1 Global Anti-Neprilysin Revenue by Type (2021 VS 2025 VS 2032)
- 5.2 Global Anti-Neprilysin Revenue by Type (2021-2032)
- 5.3 Global Anti-Neprilysin Revenue Market Share by Type (2021-2032)
6 Anti-Neprilysin Market Size by Application
- 6.1 Global Anti-Neprilysin Revenue by Application (2021 VS 2025 VS 2032)
- 6.2 Global Anti-Neprilysin Revenue by Application (2021-2032)
- 6.3 Global Anti-Neprilysin Revenue Market Share by Application (2021-2032)
7 Company Profiles
- 7.1 Novartis International AG
- 7.1.1 Novartis International AG Company Information
- 7.1.2 Novartis International AG Business Overview
- 7.1.3 Novartis International AG Anti-Neprilysin Revenue and Gross Margin (2021-2026)
- 7.1.4 Novartis International AG Anti-Neprilysin Product Portfolio
- 7.1.5 Novartis International AG Recent Developments
- 7.2 Theravance Biopharma Inc.
- 7.2.1 Theravance Biopharma Inc. Company Information
- 7.2.2 Theravance Biopharma Inc. Business Overview
- 7.2.3 Theravance Biopharma Inc. Anti-Neprilysin Revenue and Gross Margin (2021-2026)
- 7.2.4 Theravance Biopharma Inc. Anti-Neprilysin Product Portfolio
- 7.2.5 Theravance Biopharma Inc. Recent Developments
- 7.3 Pharmaleads SA
- 7.3.1 Pharmaleads SA Company Information
- 7.3.2 Pharmaleads SA Business Overview
- 7.3.3 Pharmaleads SA Anti-Neprilysin Revenue and Gross Margin (2021-2026)
- 7.3.4 Pharmaleads SA Anti-Neprilysin Product Portfolio
- 7.3.5 Pharmaleads SA Recent Developments
- 7.4 Oceanic Pharmachem Pvt. Ltd
- 7.4.1 Oceanic Pharmachem Pvt. Ltd Company Information
- 7.4.2 Oceanic Pharmachem Pvt. Ltd Business Overview
- 7.4.3 Oceanic Pharmachem Pvt. Ltd Anti-Neprilysin Revenue and Gross Margin (2021-2026)
- 7.4.4 Oceanic Pharmachem Pvt. Ltd Anti-Neprilysin Product Portfolio
- 7.4.5 Oceanic Pharmachem Pvt. Ltd Recent Developments
- 7.5 Cipla Limited
- 7.5.1 Cipla Limited Company Information
- 7.5.2 Cipla Limited Business Overview
- 7.5.3 Cipla Limited Anti-Neprilysin Revenue and Gross Margin (2021-2026)
- 7.5.4 Cipla Limited Anti-Neprilysin Product Portfolio
- 7.5.5 Cipla Limited Recent Developments
- 7.6 Bioprojet SCR
- 7.6.1 Bioprojet SCR Company Information
- 7.6.2 Bioprojet SCR Business Overview
- 7.6.3 Bioprojet SCR Anti-Neprilysin Revenue and Gross Margin (2021-2026)
- 7.6.4 Bioprojet SCR Anti-Neprilysin Product Portfolio
- 7.6.5 Bioprojet SCR Recent Developments
8 North America
- 8.1 North America Anti-Neprilysin Revenue (2021-2032)
- 8.2 North America Anti-Neprilysin Revenue by Type (2021-2032)
- 8.2.1 North America Anti-Neprilysin Revenue by Type (2021-2026)
- 8.2.2 North America Anti-Neprilysin Revenue by Type (2027-2032)
- 8.3 North America Anti-Neprilysin Revenue Share by Type (2021-2032)
- 8.4 North America Anti-Neprilysin Revenue by Application (2021-2032)
- 8.4.1 North America Anti-Neprilysin Revenue by Application (2021-2026)
- 8.4.2 North America Anti-Neprilysin Revenue by Application (2027-2032)
- 8.5 North America Anti-Neprilysin Revenue Share by Application (2021-2032)
- 8.6 North America Anti-Neprilysin Revenue by Country
- 8.6.1 North America Anti-Neprilysin Revenue by Country (2021 VS 2025 VS 2032)
- 8.6.2 North America Anti-Neprilysin Revenue by Country (2021-2026)
- 8.6.3 North America Anti-Neprilysin Revenue by Country (2027-2032)
- 8.6.4 United States
- 8.6.5 Canada
9 Europe
- 9.1 Europe Anti-Neprilysin Revenue (2021-2032)
- 9.2 Europe Anti-Neprilysin Revenue by Type (2021-2032)
- 9.2.1 Europe Anti-Neprilysin Revenue by Type (2021-2026)
- 9.2.2 Europe Anti-Neprilysin Revenue by Type (2027-2032)
- 9.3 Europe Anti-Neprilysin Revenue Share by Type (2021-2032)
- 9.4 Europe Anti-Neprilysin Revenue by Application (2021-2032)
- 9.4.1 Europe Anti-Neprilysin Revenue by Application (2021-2026)
- 9.4.2 Europe Anti-Neprilysin Revenue by Application (2027-2032)
- 9.5 Europe Anti-Neprilysin Revenue Share by Application (2021-2032)
- 9.6 Europe Anti-Neprilysin Revenue by Country
- 9.6.1 Europe Anti-Neprilysin Revenue by Country (2021 VS 2025 VS 2032)
- 9.6.2 Europe Anti-Neprilysin Revenue by Country (2021-2026)
- 9.6.3 Europe Anti-Neprilysin Revenue by Country (2027-2032)
- 9.6.4 Germany
- 9.6.5 France
- 9.6.6 U.K.
- 9.6.7 Italy
- 9.6.8 Netherlands
10 China
- 10.1 China Anti-Neprilysin Revenue (2021-2032)
- 10.2 China Anti-Neprilysin Revenue by Type (2021-2032)
- 10.2.1 China Anti-Neprilysin Revenue by Type (2021-2026)
- 10.2.2 China Anti-Neprilysin Revenue by Type (2027-2032)
- 10.3 China Anti-Neprilysin Revenue Share by Type (2021-2032)
- 10.4 China Anti-Neprilysin Revenue by Application (2021-2032)
- 10.4.1 China Anti-Neprilysin Revenue by Application (2021-2026)
- 10.4.2 China Anti-Neprilysin Revenue by Application (2027-2032)
- 10.5 China Anti-Neprilysin Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
- 11.1 Asia Anti-Neprilysin Revenue (2021-2032)
- 11.2 Asia Anti-Neprilysin Revenue by Type (2021-2032)
- 11.2.1 Asia Anti-Neprilysin Revenue by Type (2021-2026)
- 11.2.2 Asia Anti-Neprilysin Revenue by Type (2027-2032)
- 11.3 Asia Anti-Neprilysin Revenue Share by Type (2021-2032)
- 11.4 Asia Anti-Neprilysin Revenue by Application (2021-2032)
- 11.4.1 Asia Anti-Neprilysin Revenue by Application (2021-2026)
- 11.4.2 Asia Anti-Neprilysin Revenue by Application (2027-2032)
- 11.5 Asia Anti-Neprilysin Revenue Share by Application (2021-2032)
- 11.6 Asia Anti-Neprilysin Revenue by Country
- 11.6.1 Asia Anti-Neprilysin Revenue by Country (2021 VS 2025 VS 2032)
- 11.6.2 Asia Anti-Neprilysin Revenue by Country (2021-2026)
- 11.6.3 Asia Anti-Neprilysin Revenue by Country (2027-2032)
- 11.6.4 Japan
- 11.6.5 South Korea
- 11.6.6 India
- 11.6.7 Australia
- 11.6.8 Taiwan
- 11.6.9 Southeast Asia
12 South America, Middle East and Africa
- 12.1 SAMEA Anti-Neprilysin Revenue (2021-2032)
- 12.2 SAMEA Anti-Neprilysin Revenue by Type (2021-2032)
- 12.2.1 SAMEA Anti-Neprilysin Revenue by Type (2021-2026)
- 12.2.2 SAMEA Anti-Neprilysin Revenue by Type (2027-2032)
- 12.3 SAMEA Anti-Neprilysin Revenue Share by Type (2021-2032)
- 12.4 SAMEA Anti-Neprilysin Revenue by Application (2021-2032)
- 12.4.1 SAMEA Anti-Neprilysin Revenue by Application (2021-2026)
- 12.4.2 SAMEA Anti-Neprilysin Revenue by Application (2027-2032)
- 12.5 SAMEA Anti-Neprilysin Revenue Share by Application (2021-2032)
- 12.6 SAMEA Anti-Neprilysin Revenue by Country
- 12.6.1 SAMEA Anti-Neprilysin Revenue by Country (2021 VS 2025 VS 2032)
- 12.6.2 SAMEA Anti-Neprilysin Revenue by Country (2021-2026)
- 12.6.3 SAMEA Anti-Neprilysin Revenue by Country (2027-2032)
- 12.6.4 Brazil
- 12.6.5 Argentina
- 12.6.6 Chile
- 12.6.7 Colombia
- 12.6.8 Peru
- 12.6.9 Saudi Arabia
- 12.6.10 Israel
- 12.6.11 UAE
- 12.6.12 Turkey
- 12.6.13 Iran
- 12.6.14 Egypt
13 Concluding Insights
14 Appendix
- 14.1 Reasons for Doing This Study
- 14.2 Research Methodology
- 14.3 Research Process
- 14.4 Authors List of This Report
- 14.5 Data Source
- 14.5.1 Secondary Sources
- 14.5.2 Primary Sources
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst